Session P: Oral Abstracts
Tracks
.
| Friday, September 8, 2017 |
| 1:00 PM - 2:00 PM |
| Hudson I, II & III |
Speaker
Dr Zoe Ward
Senior Research Associate In Infectious Disease Modelling
University Of Bristol
The Cost-Effectiveness Of Interventions To Improve Case Finding And Engagement With Hcv Treatment For People Who Inject Drugs In The UK
1:00 PM - 1:15 PMBiography
Dr Zoe Ward is a mathematical biologist, based at the University of Bristol, interested in infectious disease dynamics, epidemiology and health economics. I am currently working on models of hepatitis C virus in populations of people who inject drugs and the impact and cost-effectiveness of harm reduction policies and treatment.
Dr Brendan Jacka
Research Associate
The Kirby Institute, Unsw Sydney
Hepatitis C Virus Phylogenetic Clustering And Latent Class Analysis Of Drug Use Among People Who Use Drugs In Vancouver Canada
1:15 PM - 1:30 PMBiography
With a background in research and diagnostic laboratories in the blood borne virus field, Brendan undertakes research identifying transmission dynamics of hepatitis C virus (HCV) amongst HIV-positive and HIV-negative patients and characterizing viral and host mutations that infer resistance/susceptibility to treatment. Brendan has expanded on his laboratory research skills to include novel analytical methods to better understand the epidemiology of infectious diseases and substance misuse.
Dr Elana Rosenthal
Associate Professor
Institute of Human Virology, University of Maryland School of Medicine
Collocation of HCV Treatment, Buprenorphine, and PrEP to Reduce Harm in PWID with HCV: Preliminary Data from the ANCHOR Study
1:30 PM - 1:45 PMBiography
Elana Rosenthal is an infectious disease physician and Assistant Professor at the Institute of Human Virology at University of Maryland School of Medicine and Clinical Director of the DC Partnership for HIV/AIDS Progress Hepatitis Clinical Research Program.
Ms Rozalyn Milne
HCV Program Coordinator, RN
Cool Aid Community Health Centre
DAA TDaa Therapy For Hcv Infection Among People With A Substance Use History Attending An Inner-City Community Health Centre - Victoria, Canada
1:45 PM - 1:50 PMBiography
Rozalyn Milne is a nurse clinician and the Hepatitis C Program Coordinator at the Cool Aid Community Health Centre in Victoria, British Columbia, Canada. Roz practices as part of an inter-disciplinary team providing infectious and chronic disease management, substance use and mental health services in the context of primary care to over 4000 patients from the region's inner-city population.
Professor Peter Vickerman
Professor In Infectious Disease Modelling
University Of Bristol
Detachable Low Dead-Space Syringes For The Prevention Of Hepatitis C Among People Who Inject Drugs: An Economic Evaluation
1:50 PM - 1:55 PMBiography
Peter Vickerman is a Professor in infectious disease modelling at the University of Bristol. He has 20-years experience in infectious disease modelling. His research focuses on using mathematical modelling to help understand the transmission of different infectious diseases and impact and cost-effectiveness of prevention measures. Specific expertise focuses on the transmission of HIV, HCV and other STIs amongst different high risk groups including injecting drug users. He has extensive experience of conducting collaborative research with organisations in varied settings.
Ms Sofia Bartlett
Phd Student
Unsw
Phylogenetic Clustering Among People With Recent Hepatitis C Virus Infection In Australia Between 2004-2015
1:55 PM - 2:00 PMBiography
Sofia Bartlett is a PhD candidate at the Kirby Institute, UNSW Sydney, and is studying transmission patterns of recently acquired hepatitis C virus infection in Australia.
